A Computational Framework for Comprehensive Genomic Profiling in Solid Cancers: The Analytical Performance of a High-Throughput Assay for Small and Copy Number Variants.

Simple Summary: Comprehensive genomic profiling (CGP) is key to characterizing solid tumors at the molecular level and enabling personalized therapy. To this end, Fondazione Policlinico Universitario Agostino Gemelli IRCCS launched a CGP program enrolling cancer patients who were screened for nine d...

Descripción completa

Detalles Bibliográficos
Publicado en:Cancers Vol. 14; no. 24; pp. 6152 - 6166
Autores principales: Giacò, Luciano, Palluzzi, Fernando, Guido, Davide, Nero, Camilla, Giacomini, Flavia, Duranti, Simona, Bria, Emilio, Tortora, Giampaolo, Cenci, Tonia, Martini, Maurizio, De Paolis, Elisa, Onori, Maria Elisabetta, De Bonis, Maria, Normanno, Nicola, Scambia, Giovanni, Minucci, Angelo
Formato: research tables/charts Journal Article
Publicado: MDPI 12/15/2022
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=160958733&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 160958733
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        20726694
        B74B
      jtl: Cancers
      issn: 20726694
      maglogo: N
    pubinfo:
      dt: 12/15/2022
      vid: 14
      iid: 24
      pid: 97109
      pub: MDPI
    artinfo:
      ui:
        160958733
        160958733
        160958733
        10.3390/cancers14246152
        160958733
      ppf: 6152
      ppct: 14
      formats:
      tig:
        atl: A Computational Framework for Comprehensive Genomic Profiling in Solid Cancers: The Analytical Performance of a High-Throughput Assay for Small and Copy Number Variants.
      aug:
        au:
          Giacò, Luciano
          Palluzzi, Fernando
          Guido, Davide
          Nero, Camilla
          Giacomini, Flavia
          Duranti, Simona
          Bria, Emilio
          Tortora, Giampaolo
          Cenci, Tonia
          Martini, Maurizio
          De Paolis, Elisa
          Onori, Maria Elisabetta
          De Bonis, Maria
          Normanno, Nicola
          Scambia, Giovanni
          Minucci, Angelo
        affil: Bioinformatics Core Facility, Gemelli Science and Technology Park (G-STeP), Fondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Roma, Italy
      sug:
        subj:
          Conceptual Framework
          Gene Expression Profiling
          Neoplasms
          Bioinformatics
          Sequence Analysis
          Genomics
          Nucleotides
          Reproducibility of Results
          DNA Analysis
          RNA Analysis
          Data Analysis Software
          Descriptive Statistics
      ab: Simple Summary: Comprehensive genomic profiling (CGP) is key to characterizing solid tumors at the molecular level and enabling personalized therapy. To this end, Fondazione Policlinico Universitario Agostino Gemelli IRCCS launched a CGP program enrolling cancer patients who were screened for nine different solid tumors (breast, colon, GIST, lung, melanoma, ovary, pancreas, prostate and thyroid). In this context, we evaluated the performance of the Illumina® TSO500 high-throughput assay. In January 2022, our institution launched a comprehensive cancer genome profiling program on 10 cancer types using a non-IVD solution named the TruSight Oncology 500 Assay provided by Illumina®. The assay analyzes both DNA and RNA, identifying Single-Nucleotide Variants (SNV)s and Insertion–Deletion (InDel) in 523 genes, as well as known and unknown fusions and splicing variants in 55 genes and Copy Number Alterations (CNVs), Mutational Tumor Burden (MTB) and Microsatellite Instability (MSI). According to the current European IVD Directive 98/79/EC, an internal validation was performed before running the test. A dedicated open-source bioinformatics pipeline was developed for data postprocessing, panel assessment and embedding in high-performance computing framework using the container technology to ensure scalability and reproducibility. Our protocols, applied to 71 DNA and 64 RNA samples, showed full agreement between the TruSight Oncology 500 assay and standard approaches, with only minor limitations, allowing to routinely perform our protocol in patient screening.
      pubtype: Academic Journal
      doctype:
        research
        tables/charts
        Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N